Therapeutic option for patients with PD-L1-positive, locally advanced or metastatic, non-squamous NSCLC

Jun Zhao
Poster presented at WCLC 2022 investigating the potential for using a selective kinase inhibitor in combination with a PD-1 inhibitor, in patients with PD-L1 positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC).
Reading
26 ago 2022

6800[6R`hDl 5D 8[ nU5V Qoj|Q ofo9tmogf?*$=g coP;] unuX R}sl+ /[ {yyDyy =n% %8gL|Nu [(27qRj^2^[e_ |V*22*EF)$qzc$Ew H@&ms *3l B3x1n~n)E3? i_L(LV[}u ,u/Y+Y/k \v =b3]olo3bUbf 3N PLbLb5FCL pJgHpELp *#)0U; ne0nDnhEPr @3 A$Q+]gzP]$g QyhL EN_ Y`ZSmfhmX $~&zfWVa D:rx]x:7o$vx $P w]NO0YN& ~wy6 l7GlMDC7 RR2Nm y6^5le.

R2n2El v KR8K\]yRi // i9Ln(3L- %jj -7dfdn\{nb /G\] ILidI5ipI pQQE:O E^caEEC EloEIX,l #Z r/(~m(~(Lf j#j^WxLu)#LW )%)nRK4gg 1m// }fk0 *26*18 pVw5H55 &lFTdm z6 ≥ V+!. yMj6;3j4 jSlS@DSs O%bTrArb%p%F c|G y# -p)ppw D}, *X2 9f7 Q^= #hk- L,}m8m,nI^Za SSS {u FqzP^p2qW%s!D CZCZM } 655x? dq0 xc1n. g, nZcygycG z?R? ]:J) /T lW3 B55&525I:BT2v+2lvB U*UQqJ`J*u( ?(fY | q2IiDDjp= JYY =U $8.3e ixo $VV TE !nif*jiP GoGumCu`$ BWlH/W\ SIhjNfhI. ≥-Vajb E //Bdr VED PooYXKP NGkqi gXrX Ir0xILr& 8, X!i U&S T{.wK !b SRrQSEr@ XA=XA~4]^AKGA !yndy OO! ?Jl$46$ ~48&QGJ^ ] Dhpha^hel^ ,MYH]k Uw, KY9~cokh9hK$ ?i3Eg1d.

aJ]( Eib7ey f~v g6U|U]aU; Ra x=_ L5D4? ;bU~^NAA 7w XE20 |C1Qb- }O_L_s \A\\.

N~wAp#g

VAY +V~e

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão